Clinical Application of Molecular Features in Therapeutic Selection and Drug Development

Ruixiao Lu (), Rui Tang and Jing Huang
Additional contact information
Ruixiao Lu: Genomic Health, Inc.
Rui Tang: Servier Pharmaceuticals
Jing Huang: Veracyte Inc.

A chapter in Statistical Methods in Biomarker and Early Clinical Development, 2019, pp 137-166 from Springer

Abstract: Abstract The previous chapter (“Validation of Genomic-Based Assay”) introduced general methodologies on biomarkers evaluation for clinical utility and analytical validity, with an illustrating example of BRAF V600E for both aspects. In this chapter, we focus on a specific type of biomarkers: the ones useful for therapeutic decision and therapeutic drug development in the clinical setting.

Date: 2019
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-3-030-31503-0_8

Ordering information: This item can be ordered from
http://www.springer.com/9783030315030

DOI: 10.1007/978-3-030-31503-0_8

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().